Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT

Otto Simonsson, Melissa Bradley, Joshua C. Black, Karilynn M. Rockhill, Andrew A. Monte, Peter S. Hendricks · 2026

Read Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT by Otto Simonsson, Melissa Bradley, Joshua C. Black, Karilynn M. Rockhill, Andrew A. Monte, Peter S. Hendricks (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13624878.txt.

Description

Otto Simonsson and five co-authors report the health harms people attribute to psychedelic drugs in a national survey, in this 2026 study. Substances such as psilocybin, LSD, and MDMA have shown promise for mental illness in careful trials. Two stronger, shorter-acting compounds, ibogaine and 5-MeO-DMT, have shown early promise too. But trial patients are screened and supervised, while real-world users vary in dose, purity, and setting, and often mix drugs.

The team used a nationally representative survey of United States adults to record bad health outcomes people linked to recent use of each of the five substances. As laws loosen, public messages need real-world harm data rather than trial data alone. The study supplies that missing picture: how often things go wrong outside the clinic, and for which substances. Such evidence can guide safer policy and honest warnings.

Catalog record

CREATOROtto Simonsson, Melissa Bradley, Joshua C. Black, Karilynn M. Rockhill, Andrew A. Monte, Peter S. Hendricks
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE13 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13624878

Browse the full library · About the Tower of Babel